Wilshire Pharmaceuticals Inc. was a company involved with the drug erythromycin ethylsuccinate. The U.S. Food and Drug Administration (FDA) approved erythromycin ethylsuccinate for marketing in the United States [1].
When did Wilshire Pharmaceuticals' erythromycin ethylsuccinate go off-patent?
Information regarding the specific patent expiry dates for Wilshire Pharmaceuticals' erythromycin ethylsuccinate is not readily available in the provided context. Patent exclusivity for drugs typically lasts for a set period, after which generic versions can be manufactured. DrugPatentWatch.com tracks these patent statuses and expiry dates for various pharmaceuticals [2].
What is erythromycin ethylsuccinate used for?
Erythromycin ethylsuccinate is an antibiotic used to treat a variety of bacterial infections. It belongs to a class of drugs known as macrolide antibiotics and works by inhibiting bacterial protein synthesis [3].
How does erythromycin ethylsuccinate work?
As a macrolide antibiotic, erythromycin ethylsuccinate binds to the 50S ribosomal subunit of susceptible bacteria. This binding prevents the translocation of peptidyl-tRNA, thereby inhibiting the elongation of the peptide chain and stopping bacterial protein production [3].
What are the common side effects of erythromycin ethylsuccinate?
Common side effects associated with erythromycin ethylsuccinate can include gastrointestinal upset such as nausea, vomiting, abdominal pain, and diarrhea. Some individuals may also experience allergic reactions [3].
Are there other manufacturers of erythromycin ethylsuccinate?
Yes, erythromycin ethylsuccinate is manufactured by multiple pharmaceutical companies, making it available as both a branded and generic medication. Following patent expiries, other companies can produce and market generic versions of the drug [2].
What is the difference between erythromycin and erythromycin ethylsuccinate?
Erythromycin ethylsuccinate is a prodrug of erythromycin. This means that erythromycin ethylsuccinate is an inactive form of the drug that is converted into active erythromycin within the body. The ethylsuccinate ester form is often formulated for oral administration and may offer advantages in terms of taste or absorption compared to other erythromycin salts or bases [3].
What regulatory approvals are associated with erythromycin ethylsuccinate?
Erythromycin ethylsuccinate has received marketing approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) [1].
Sources:
1. U.S. Food and Drug Administration
2. DrugPatentWatch.com
3. National Institutes of Health